Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue, and revisiting drugs with a focus on brain tumor penetration may yield surprises. Clin Cancer Res; 24(2); 256–8. ©2017 AACR.
See related article by Byron et al., p. 295
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2Dh0WNa
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου